First- and second-line therapy and deaths
| Second-line treatment . | Single-agent anti-CD20 Ab or RT alone, N = 37 . | CT ± anti-CD20 Ab ± RT, N = 27 . | HDCT + ASCT, N = 31 . | No treatment, N = 4 . | Total, N = 99 . |
|---|---|---|---|---|---|
| First-line treatment, n/N (%) | |||||
| RT alone: MOT = 12.2 y, 3 deaths | 6/20 (30) | 13/20 (65) | 1/20 (5) | — | 20/20 (100) |
| CT ± RT: MOT = 11.2 y, 12 deaths | 26/73 (36) | 13/73 (18) | 30/73 (41) | 4/73 (5) | 73/73 (100) |
| Anti-CD20 Ab: MOT = 5.6 y, no death | 5/6 (83) | 1/6 (17) | — | — | 6/6 (100) |
| Deaths, n (%) | 1 (3) | 6 (22) | 5 (16) | 3 (75) | 15 (15) |
| Cause of death, n | |||||
| NLPHL | — | 4 | 3 | 2 | 9 |
| Infectious complication | 1 | — | 1 | 1 | 3 |
| Second malignancy | — | 2* | 1† | — | 3 |
| Second-line treatment . | Single-agent anti-CD20 Ab or RT alone, N = 37 . | CT ± anti-CD20 Ab ± RT, N = 27 . | HDCT + ASCT, N = 31 . | No treatment, N = 4 . | Total, N = 99 . |
|---|---|---|---|---|---|
| First-line treatment, n/N (%) | |||||
| RT alone: MOT = 12.2 y, 3 deaths | 6/20 (30) | 13/20 (65) | 1/20 (5) | — | 20/20 (100) |
| CT ± RT: MOT = 11.2 y, 12 deaths | 26/73 (36) | 13/73 (18) | 30/73 (41) | 4/73 (5) | 73/73 (100) |
| Anti-CD20 Ab: MOT = 5.6 y, no death | 5/6 (83) | 1/6 (17) | — | — | 6/6 (100) |
| Deaths, n (%) | 1 (3) | 6 (22) | 5 (16) | 3 (75) | 15 (15) |
| Cause of death, n | |||||
| NLPHL | — | 4 | 3 | 2 | 9 |
| Infectious complication | 1 | — | 1 | 1 | 3 |
| Second malignancy | — | 2* | 1† | — | 3 |